Improving pulmonary surfactants

Acta Pharmacologica Sinica

Volumn 23, Issue SUPPL., 2002, Pages 11-15

  Taeusch, H William ^a   Lu, Karen ^a   Ramierez Schrempp, Daniela ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; KL 4; LUNG SURFACTANT EXTRACT; LUSUPULTIDE; PORACTANT; SF RI 1; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; SURFACTANT TA; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG DETERMINATION; DRUG EFFICACY; DRUG RESEARCH; HUMAN; HYALINE MEMBRANE DISEASE; LIPID COMPOSITION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; PROTEIN DETERMINATION;

EID: 0036817521     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55-9.
2. Chiesi Farmaceutici. Curosurf Package Insert. Package Insert; NDA 20-744: 1-7.
3. Bridges J, Davies H, Damodarasamy M, Kuroki Y, Howles G, Hui D, et al. Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury. J Biol Chem 2000; 49: 38848-55.
4. Kruger P, Schalke M, Wang Z, Notter R, Dluhy R. Effect of hydrophobic surfactan peptides SP-B and SP-C on binary phospholipid monlayers. I. Fluorescence and dark-field microscopy. Biophys J 1999; 77: 9-3-914.
5. Notter R. Lungs Surfactants: Basic Science and Clinical Applications, Lung Biology in Health and Disease. NY: Marcel Dekker; 2000.
6. Lachmann B, Robertson B, Vogel J. In vivo lung lavage as an experimental model of the respiratory distress syndrome. Acta Anaesthesiol Scand 1980; 24: 231-6.
7. Cummings JJ, Holm BA, Hudak ML, Hudak BB, Fergusen WH, Egan EA. A controlled clinical comparison of four different surfactant preparations in surfactant deficient lambs. Am Rev Respir Dis 1992; 145: 999-1004.
8. Rider E, Ikegami J, Whitsett J, Hull W, Absolom D, Jobe A. Treatment responses to surfactants containing natural surfactant proteins in preterm rabbits, Am Rev Res Dis 1993; 147: 669-76.
9. Kobayashi T, Tashiro K, Yamamoto K, Nitta S, Ohmura S, Suzuki Y, Effects of surfactant proteins SP-B and SP-C on dynamic and static mechanics of immature lungs. J Appl Physiol 1997; 83: 1849-56.
10. Robertson B, Kobayashi T, Ganzuka M, Grossmann G, Li W, Suzuki Y. Experimental neonatal respiratory failure induced by a monoclonal antibody to the hydrophobic surfactant-associated protein SP-B. Pediatr Res 1991; 30: 239-43.
11. Tokieda K, Whitsett J, Clark J, Weaver T, Ikeda K, McConnell K, et al. Pulmonary dysfunction in neonatal SP-B deficient mice. Am J Physiol 1997; 273: 1849-56.
12. Walther F, Hernandez-Juviel J, Bruni R, Waring A. Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats. Am J Respir Crtit Care Med 1997; 156: 855-61.
13. Hlastala M, Souders J. Perfluorocarbon enhanced gas exchange: The easy way. Am J Respir Crit Care Med 2001; 164: 1-2.
14. Spragg R. Treatment of patients with rSP-C surfactant. Conference Proceedings: Pathology of the Surfactant System of the Mature Lung 1999: 373-5.
15. Taeusch HW, Keough KMW. Inactivation of pulmonary surfactant and the treatment of acute lung injuries. Pediatr Pathol Mol Med 2001; 20: 519-36.
16. Taeusch H, Lu K, Goerke J, Clements J. Nomonic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 1999; 159: 1391-5.
17. Stichtenoth G, Curstedt T, Robertson B, Herting E. Increasing the resistance of Curosurf to meconium inactivation by adding lipids, phospholipids, or dextran [abstract]. Biol Neonate 2001; 80 (Suppl): 39.
18. Lu K, Taeusch H, Robertson B, Goerke J, Clements J. Polyethylene glycol/surfactant mixtures improve lung function after HC1 and endotoxin lung injuries. Am Rev Respir Crit Care Med 2001; 164: 1531-6.
19. Kobayashi T, Tashiro K, Cui X, Konzaki T, Xu Y, Kabata C, Yamamoto K. Experimental models of acute respiratory distress syndrome: Clinical relevance and response to surfactant therapy. Biol Neonate 2001; 80 (Suppl 1): 26-8.
20. Calkovska A, Some M, Linderholm B, Johansson J, Curstedt T, Robertson B. Biophysical and physiological properties of Curosurf enriched with polymyxin B. Biol Neonate 2002; 81 (Suppl): 30.
21. Postle A, Heeley E, Wilton D. A comparison of the molecular species compositions of mamalian lung surfactant phospholipids. Comp Biochem Physiol 2001; 129 (Pt a): 65-73.
22. Robertson B, Taeusch H. Surfactant therapy for lung disease, lung biology in health and disease. NY: Marcel Dekker; 1985.
23. Seeger W, Grube C, Gunther AW, Schmidt R. Surfactant inhibition by plasma proteins: Differential sensitivity of various surfactant preparations. Eur Respir J 1993; 6: 971-7.
24. Bernhard W, Mottaghian J, Gebert A, Rau GA, von Der Hardt H, Poets CF. Commercial versus native surfactants. Surface activity, molecular coponets, and the effect of calcium. Am J Respir Crit Care Med 2000; 162 (4 Pt 1): 1524-33.
25. Kahn M, Anderson G, Amyan W, Hall S. Phosphatidylcholine molecular species of calf lung surfactant. Am J Physiol 1995; 13: L567-73.
26. ONY I. Infasurf (Calfactant). Package Insert 1998.
27. Bloom B, Kattwinkel J, Hall R, Delmore P, Egan E, Trout J, et al. Comparison of Infasurf (Calf Lung Surfactant Extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997; 100: 31-8.
28. Ross A. Survanta (Beractant). Package Insert 1999.
29. Wellcome G. Exosurf Neonatal, Product Information. 1996: 1-15.
30. Haagsman HP, van Eijk M, Walch M, Putz G. Protein composition and surface activity of commercial surfactant preparations. Am J Respir Crit Care Med 1997; 155 (2 Pt 2): A213.
31. Cheng G, Ueda T, Numao T, Kuroki Y, Nakajima H, Fukushima Y, et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur Respir J 2000; 16: 831-5.
32. Lu K, Taeusch H. Polymer effects differ with Survanta, Curosurf and Infasurf [abstract]. J Invest Med 2001; 49: 28A.